Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$37.76MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Neil F. McFarlane
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Beta
- 0.99
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 4.73
Financials
Revenue
$37.76M+229.4%Net Income
$19.21MEBITDA
$20.03MFree Cash Flow
$9.81MEPS (diluted)
$0.26Shares Outstanding (diluted)
61.73M+6643.5%Operating Expenses
$24.07MCash & Debt
$195.57MReturn of Capital
$0.00Revenue by Segment (annual)
$18.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $106.47M | $83.23M | $1.40 |
| 2024 | $23.61M | $-105.51M | $-2.28 |
| 2023 | $27.46M | $-46.05M | $-1.30 |
| 2022 | $10.16M | $-26.77M | $-0.78 |
| 2021 | $28.65M | $-8.55M | $-2.11 |
| 2020 | $13.29M | $-12.76M | $-3.21 |
| 2019 | $12.84M | $-24.52M | $-13.23 |
| 2018 | $0.00 | $-56.47M | $-50.39 |
| 2017 | $0.00 | $-43.39M | $-47.37 |
| 2016 | $0.00 | $-16.52M | $-18.10 |
| 2015 | $0.00 | $-54.66M | $-118.69 |
| 2014 | $0.00 | $-24.45M | $-31.79 |
| 2013 | $0.00 | $-5.23M | $-10.69 |
| 2012 | $0.00 | $-70.4K | $-0.47 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $2.21
- Implied price
- $13.27
- Return from $8.76
- 8.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $6.60 — -24.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 2 | 4 | 6 | 8 | 10 |
|---|---|---|---|---|---|
| -2.0% | -20.9% | -9.1% | -1.4% | 4.4% | 9.2% |
| 3.0% | -16.8% | -4.4% | 3.6% | 9.8% | 14.8% |
| 8.0% | -12.8% | 0.2% | 8.7% | 15.1% | 20.3% |
| 13.0% | -8.7% | 4.8% | 13.7% | 20.4% | 25.9% |
| 18.0% | -4.7% | 9.5% | 18.7% | 25.7% | 31.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30-50.00%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·4d ago·Negative
Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company committed to redefining what's possible in bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra's executive leadership team will present at the Piper Sandler 38th Annual Healthcare Conference in New York, NY on Wednesday, Dece…
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Zevra Therapeutics, Inc. (ZVRA) Q3 2026 Earnings Call Transcript Zevra Therapeutics, Inc. (ZVRA) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
Zevra Therapeutics Q3 Earnings Call Highlights Zevra Therapeutics NASDAQ: ZVRA reported third-quarter 2026 net revenue of $37.8 million, up 45% from $26.1 million a year earlier, driven primarily by U.S. sales of MIPLYFFA for Niemann-Pick disease type C, or NPC.
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced it will report corporate and financial results for the third quarter on Tuesday, November 3, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4…
View source ↗ - Newsseekingalpha.com·38d ago·Negative
Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal Zevra Therapeutics is rated Buy, with a fair value of $13.38 per share, 28.7% above current levels. ZVRA's valuation is anchored by $260.2M in cash and a drug business priced at less than a fifth of its rival's acquisition value. Miplyffa's US launch is slow but stable; key risks are insurer restrictions and potential sales declines, with Europe currently valued at zero.
View source ↗ - Newsseekingalpha.com·47d ago·Positive
Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor Zevra Therapeutics is a buy-rated, single-asset rare disease play with Miplyffa driving strong U.S. growth and early profitability. 2Q26 net revenue reached $39.7M, up 53% YoY, with Miplyffa contributing $30.2M and high patient retention supporting a durable franchise thesis. Management's diagnosis expansion efforts suggest the NPC addressable market may be up to 900 patients, extending the growth runway beyond i
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
Zevra Therapeutics to Present at Upcoming Investor Conferences BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra's executive leadership team will present at the following investor conferences in New York, NY.
View source ↗ - Newsglobenewswire.com·89d ago·Positive
…ta on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the presentation of two posters featuring long-term real-world data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC) at the Society for the Stu…
View source ↗
Earnings
Mon, Mar 8(in 4 months)
Consensus estimate $0.19 per share
Typical surprise +65.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$0.26 vs $0.16beat
- Wed, Aug 5$0.14 vs $0.11beat
- Wed, May 6$0.60 vs $0.06beat
- Mon, Mar 9$0.21 vs $0.05beat
- Wed, Nov 5$-0.01 vs $-0.02beat
- Tue, Aug 12$1.21 vs $2.19miss
Estimates and results for ZVRA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ZVRA officers and directors.
- Bought
- $310k
- Sold
- $3.9m
5 trades
20 trades
- Mcfarlane Neil F.sold
- Thompson Rahsaansold
- Watton Corey Michaelsold
- Thompson Rahsaansold
- Thompson Rahsaansold
- Mcfarlane Neil F.sold
- Sangiovanni Timothy J.sold
- Schafer Joshuasold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ZVRA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
